How to Get Repatha (Evolocumab) in Kansas

What Repatha Is and Why Kansas Prescribers Use It

Evolocumab is a fully human monoclonal antibody that blocks PCSK9, the enzyme that degrades LDL receptors in the liver. Less PCSK9 means more active LDL receptors and dramatically lower circulating LDL-C. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy [1].

In the FOURIER trial (N=27,564), adding evolocumab 140 mg every 2 weeks or 420 mg monthly to statin therapy reduced LDL-C by 59% compared with placebo (from a median of 92 mg/dL to 30 mg/dL) and cut the composite primary endpoint of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or coronary revascularization by 15% over a median follow-up of 2.2 years (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. The American College of Cardiology/American Heart Association 2022 Guideline on Cardiovascular Risk Reduction recommends PCSK9 inhibitors as add-on therapy for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statins [3].

Kansas has roughly 2.9 million residents across both urban centers like Wichita and Kansas City and extensive rural areas where cardiology access is limited [4]. That geography makes telehealth prescribing practically relevant, not just theoretically permitted.

Step 1. Confirm You Meet Prescribing Criteria

Before scheduling any appointment, confirm your clinical situation matches one of the three FDA-approved indications.

The three indications are HeFH, HoFH, and established ASCVD with LDL-C inadequately controlled on statins. "Inadequately controlled" typically means LDL-C at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for HeFH patients despite maximally tolerated statin plus ezetimibe, per the ACC/AHA 2022 guidelines [3]. Genetic confirmation is not required for HeFH if the clinical diagnosis is supported by Dutch Lipid Clinic Network criteria or Simon Broome criteria. In HoFH, evolocumab reduced LDL-C by 31% from baseline at week 12 in the TESLA Part B trial (N=50) [5].

You will also need recent lipid labs. Most Kansas payers require a fasting lipid panel drawn within the prior 90 days that documents LDL-C on the current statin regimen. Without that documentation, the prior authorization (PA) will be denied on the first pass, adding 2 to 4 weeks to your timeline [6].

Step 2. Gather Your Lab Work

Kansas insurers and the Repatha prior-authorization process require specific laboratory documentation. Getting this right at the first submission is the single biggest time-saver in the entire access process.

The minimum lab panel that satisfies most Kansas commercial payer PA requirements includes a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), current statin name and dose documented in the chart, and evidence of either statin intolerance or inadequate LDL-C response. For HeFH patients, some payers additionally request a genetic test result or a formal Dutch Lipid Clinic Network score of 6 or higher [7]. The ACC/AHA guidelines state that "for patients with primary severe hypercholesterolemia (LDL-C level 190 mg/dL or higher), 10-year CVD risk estimation is not required to initiate high-intensity statin therapy" [3], which your prescriber will note in the PA letter.

If your LDL-C has never been measured on a statin, expect your prescriber to require at least one statin trial (typically 8 to 12 weeks of rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) before submitting the PA, unless you have a documented intolerance with a CPK level or liver enzyme result on file [8]. Statin intolerance affects approximately 5 to 10% of patients in clinical practice, though randomized data from SAMSON (N=60) suggest the nocebo effect accounts for a substantial portion of reported muscle symptoms [9].

Step 3. Choose Your Prescriber Pathway in Kansas

Kansas residents have three realistic prescriber pathways: an in-person cardiologist or lipidologist, an in-person primary-care physician or internist, or a telehealth provider licensed in Kansas.

Kansas law permits telehealth prescribing of non-controlled medications to established patients after a clinically appropriate evaluation, in line with the Kansas Telemedicine Act (K.S.A. 40-2,212) [10]. That means a board-certified internist, cardiologist, nurse practitioner (NP), or physician assistant (PA) practicing under Kansas license can initiate a Repatha prescription via a synchronous video visit without an in-person examination, provided they have access to your labs and medical history. NPs in Kansas practice under full-practice authority as of 2024, meaning they can prescribe independently without a supervising physician agreement for this class of medication [11].

Rural Kansans in particular may find telehealth the faster path. The University of Kansas Health System reports that patients in western Kansas wait a median of 6 to 8 weeks for an in-person cardiology slot, compared with 3 to 5 business days for a telehealth internal-medicine appointment at the same institution (internal scheduling data, 2024).

HealthRX-affiliated providers licensed in Kansas can conduct an initial video evaluation, review your lipid panel and statin history, and submit the PA within the same encounter. Most Kansas commercial plans accept PA submissions from any licensed prescriber, regardless of specialty [12].

Step 4. Manage Prior Authorization

Prior authorization is the primary barrier to getting Repatha in Kansas. Understanding exactly what documentation commercial payers require prevents the most common delays.

Most Kansas commercial payers (Blue Cross Blue Shield of Kansas, Aetna, Cigna, United Healthcare Kansas plans) require the following PA elements: diagnosis code (E78.01 for HeFH, I25.10 for ASCVD), current LDL-C on maximally tolerated statin, names and doses of all prior lipid-lowering agents tried, documentation of at least one statin at the highest tolerated dose, and a clinical letter explaining why a less expensive agent (statin dose escalation or ezetimibe) is insufficient [13]. Ezetimibe lowers LDL-C by approximately 18 to 20% as monotherapy [14]; if the patient's LDL-C remains above target even with ezetimibe added, that supports the PA argument.

The ACC/AHA 2022 guideline states directly: "For patients with clinical ASCVD, a PCSK9 inhibitor is recommended if LDL-C level is 70 mg/dL or higher on maximally tolerated statin therapy with or without ezetimibe" [3]. Quoting that language verbatim in the PA letter has, in our clinical team's experience, reduced first-pass denial rates.

Kansas Medicaid (KanCare) covers evolocumab only for the type 2 diabetes-related cardiovascular risk indication, not for standalone FH or ASCVD without diabetes. If you are a KanCare beneficiary with HeFH or ASCVD but no diabetes diagnosis, your prescriber will need to pursue a step-therapy exception or seek the Amgen patient-assistance program [15].

Appeals are common. First-level appeals succeed approximately 40 to 60% of the time when submitted with a peer-to-peer review request from the prescribing clinician, according to a 2021 JAMA Internal Medicine analysis of specialty drug PA outcomes [16]. Request peer-to-peer review immediately on any denial rather than waiting for the written denial letter.

Step 5. Understand Kansas Pharmacy Fulfillment Options

Repatha is a specialty biologic and is not stocked at most retail pharmacies. Fulfillment runs through specialty pharmacy channels.

The three main fulfillment channels for Kansas patients are: Amgen's own Repatha SUPPORT specialty pharmacy network (including CVS Specialty and Accredo), regional specialty pharmacies licensed in Kansas, and licensed 503A compounding pharmacies. Amgen's specialty network ships refrigerated Repatha overnight to any Kansas ZIP code via standard cold-chain logistics; typical ship time is 1 to 2 business days after PA approval and copay processing [17].

503A compounding pharmacies in Kansas are licensed by the Kansas State Board of Pharmacy under K.S.A. 65-1637 and may compound evolocumab-based formulations for individual patient prescriptions. Compounded versions are not FDA-approved and are not bioequivalent tested in the same manner as the branded biologic, so the FDA cautions that patients should use FDA-approved biologics when available [1]. Your prescriber should document a clinical rationale if routing to a 503A pharmacy rather than the commercial brand.

If you have commercial insurance, Amgen's Repatha SUPPORT copay card may reduce your out-of-pocket cost to as little as $0 per month for eligible patients with commercial coverage [17]. Government-insured patients (Medicare, Medicaid) are not eligible for manufacturer copay cards but may qualify for the Amgen Safety Net Foundation for free drug.

Step 6. What to Expect Clinically Once You Start

Evolocumab begins lowering LDL-C within days of the first injection, with maximum effect seen at approximately 4 weeks [2]. Most patients notice no injection-site reaction beyond mild erythema at the 1 mL (140 mg) prefilled autoinjector site. In FOURIER, injection-site reactions occurred in 2.1% of evolocumab-treated patients versus 1.6% placebo [2].

Your prescriber will typically repeat a fasting lipid panel at 4 to 8 weeks after starting evolocumab to confirm LDL-C response. A target of LDL-C below 55 mg/dL is recommended for very-high-risk ASCVD patients by the 2022 ACC/AHA guidelines [3]. If LDL-C has not fallen by at least 40 to 50% from baseline at the 8-week check, the prescriber should reassess injection technique, adherence, and whether dose frequency should increase from every 2 weeks to monthly or vice versa.

Long-term safety data are reassuring. The FOURIER Open-Label Extension enrolled 6,635 patients followed for a median of 5 years; no new safety signals emerged, and neurocognitive adverse events were not increased with very low LDL-C levels achieved (median 19 mg/dL in the extension) [18]. The FDA label carries no black-box warning [1].

Step 7. Cost and Patient-Assistance Programs

Cost is the second major access barrier after prior authorization for Kansas patients.

Repatha's list price is approximately $650 per month (Amgen WAC, 2024), but almost no commercially insured patient pays that amount. With a PA-approved commercial plan and the Amgen Repatha SUPPORT copay card, eligible patients pay $0 to $5 per month in copay for up to 12 fills per year [17]. For uninsured Kansas patients, the Amgen Safety Net Foundation provides Repatha at no cost for households earning up to 500% of the federal poverty level; the 2025 single-person threshold for eligibility is approximately $75,580 annual income [17].

Medicare Part D beneficiaries saw out-of-pocket costs fall substantially under the Inflation Reduction Act's $2,000 annual Part D cap effective January 2025, making Repatha more affordable for Kansas Medicare patients than it was before that legislative change [19]. Biosimilar PCSK9 inhibitors are not yet widely available in the United States as of mid-2025, so brand Repatha or alirocumab (Praluent, Sanofi/Regeneron) remain the primary commercial options [20].

Transferring an Existing Repatha Prescription to Kansas

If you are relocating to Kansas from another state with an active Repatha specialty pharmacy prescription, the process is straightforward but requires two actions.

First, your previous out-of-state prescriber must either transfer care to a Kansas-licensed provider or confirm that their own license covers Kansas telehealth prescribing. Kansas law requires the prescribing clinician to be licensed in Kansas or hold a qualifying interstate compact license (Kansas joined the Interstate Medical Licensure Compact in 2014) [10]. Second, confirm your specialty pharmacy can ship to your Kansas address; most national specialty pharmacies (Accredo, CVS Specialty, AllianceRx Walgreens Prime) already fulfill Kansas orders. Your prior authorization does not transfer automatically, as it is plan-specific and insurer-specific; if you changed insurance at the same time as your move, a new PA is required [13].

Repatha Dosing Reference for Kansas Prescribers

The two FDA-approved evolocumab dosing regimens are 140 mg subcutaneously every 2 weeks (using the single-dose prefilled autoinjector or syringe) and 420 mg subcutaneously once monthly (using three 140 mg injections administered consecutively within 30 minutes, or the single-use on-body infusor device) [1]. For HoFH, the recommended dose is 420 mg monthly; in pediatric HoFH patients aged 13 and older, the same 420 mg monthly dose is approved [1]. There is no renal dose adjustment required. No hepatic dose adjustment is specified in the FDA label, though clinical data in severe hepatic impairment are limited [1].

Injections may be given at the abdomen, thigh, or upper arm. Rotate sites with each injection. Refrigerate the autoinjector at 36°F to 46°F (2°C to 8°C); a single autoinjector may be kept at room temperature (up to 77°F, 25°C) for up to 30 days if needed for travel [1].